Definium Therapeutics (DFTX) Total Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Total Current Liabilities data on file, last reported at $81.1 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $81.1 million, up 166.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.1 million (up 166.11% YoY), and the FY2025 annual result was $66.7 million, up 71.69% from the prior year.
• Total Current Liabilities improved to $81.1 million in Q1 2026 per DFTX's latest filing, from $66.7 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $81.1 million in Q1 2026 and troughed at $7.9 million in Q2 2022.
• A 5-year average of $38.0 million and a median of $33.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 346.21% in 2023, then sank 53.3% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $17.9 million in 2022, then jumped by 80.23% to $32.2 million in 2023, then advanced by 20.48% to $38.8 million in 2024, then surged by 71.69% to $66.7 million in 2025, then increased by 21.61% to $81.1 million in 2026.
• Business Quant data shows DFTX's Total Current Liabilities at $81.1 million in Q1 2026, $66.7 million in Q4 2025, and $65.4 million in Q3 2025.